<DOC>
	<DOCNO>NCT00718588</DOCNO>
	<brief_summary>This Phase I multicenter study conduct United States consist double-blind , placebo-controlled , SAD stage , follow double-blind , placebo control MAD stage . The study conduct approximately 65 adult patient 18 80 year old RA .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics , Pharmacodynamics MTRX1011A Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . SAD Stage RA diagnose accord ACR For patient take antirheumatic therapy , receipt stable regimen prior randomization Previous treatment biologic agent , include antiTNF agent , permit discontinue appropriate washout period 2 . MAD Stage ( addition follow ) Failure least one biologic agent , define lack loss response intolerance Active disease define swollen tender count Significant systemic involvement RA , include vasculitis , pulmonary fibrosis , Felty 's syndrome Malignancy , prior malignancy , nonmelanoma skin cancer cervical carcinoma situ resect History treatment T celldirected therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>RA</keyword>
</DOC>